CDK4/6 INHIBITION IN ADVANCED CHORDOMA: FINAL RESULTS OF THE NCT PMO-1601 TRIAL.
Ottobre 7, 2025/da LuisaPRESS RELEASES OF INDUSTRY-SPONSORED CLINICAL TRIALS IN ONCOLOGY: CHARACTERISTICS, TIMING AND FINANCIAL IMPACT.
Settembre 30, 2025/da LuisaSURVIVAL OF PATIENTS WITH LUNG ADENOCARCINOMA DIAGNOSED IN 2000, 2010, AND 2020.
Settembre 23, 2025/da LuisaALLIANCE AGAINST CANCER 18-20 SETTEMBRE-VERONA 10TH ANNUAL MEETING: NEW TECHNOLOGIES AND STRATEGIES TO FIGHT CANCER
Settembre 16, 2025/da LuisaPLATELET TRANSFUSION: 2025 AABB AND ICTMG INTERNATIONAL CLINICAL PRACTICE GUIDELINES.
Settembre 16, 2025/da LuisaUNIMI-MASTER UNIVERSITARIO DI I LIVELLO: MASTER TLSB NOVEMBRE 2025-NOVEMBRE 2026
Settembre 15, 2025/da LuisaTRASTUZUMAB DERUXTECAN (T-DXd)+PERTUZUMAB (P) vs TAXANE+TRASTUZUMAB+PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (pts) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) ADVANCED/METASTATIC BREAST CANCER (a/mBC): INTERIM RESULTS FROM DESTINY-BREAST09
Settembre 9, 2025/da Luisa12-13 SETTEMBRE 2025 LECCE-TERAPIE INNOVATIVE NEL CARCINOMA MAMMARIO E NELLE NEOPLASIE GINECOLOGICHE
Settembre 2, 2025/da LuisaPERIOPERATIVE DURVALUMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER.
Settembre 2, 2025/da LuisaAIGOM-2025 CARCINOMA MAMMARIO METASTATICO: QUALI NOVITA’? WEBINAR 10 OTTOBRE 2025
Agosto 4, 2025/da LuisaNOVEL THERAPIES FOR PANCREATIC CANCER.
Luglio 22, 2025/da LuisaENCORAFENIB, CETUXIMAB, AND mFOLFOX6 IN BRAF-MUTATED COLORECTAL CANCER.
Luglio 14, 2025/da Luisa
Scorrere verso l’alto
